MarketWatch | Nov 6 | Applied Biosystems and Asuragen will work with the Predictive Safety Testing Consortium to develop a predictive gene signature panel that will allow pharmaceutical companies to quickly and easily screen potential therapeutics for toxic effects in pre-clinical samples. MarketWatch